Antifungal Susceptibility of Clinical Isolates and Artificially Produced Multi-azole-resistant Strains of Cryptococcus neoformans (formerly: Cryptococcus grubii) to Ravuconazole

被引：8

作者：

Kano, Rui ^{[1
]}

Sugita, Takashi ^{[2
]}

Kamata, Hiroshi ^{[1
]}

机构：

[1] Nihon Univ, Dept Vet Pathobiol, Coll Bioresouce Sci, 1866 Kameino, Fujisawa, Kanagawa 2520880, Japan

[2] Meiji Pharmaceut Univ, Dept Microbiol, Kiyose, Tokyo, Japan

来源：

MEDICAL MYCOLOGY JOURNAL | 2020年 / 61卷 / 01期

关键词：

antifungal susceptibility; azole; Cryptococcus neoformans; multi-azole resistance; ravuconazole; FELINE CRYPTOCOCCOSIS;

D O I：

10.3314/mmj.19-00016

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

Ravuconazole (RVCZ) is a newly available human azole drug in Japan since 2018 and is a broad-spectrum antifungal agent that exhibits excellent activity against Candida albicans and Cryptococcus neoformans (formerly: Cryptococcus grubii). The drug is also highly active against isolates that are resistant to fluconazole (FLCZ). In the present study, the in vitro susceptibility to ravuconazole (RVCZ) of Japanese clinical isolates and multi-azole-resistant strains of C. neoformans was investigated using the Clinical & Laboratory Standards Institute (CLSI) M27-A3 test. The minimum inhibitory concentrations for the 14 clinical isolates and the multi-azole-resistant strains were 0.003125-0.125 mg/L and 0.25-0.5 mg/L for RVCZ, respectively. RVCZ is as effective as ITCZ and VRCZ for treating clinical isolates from cats and humans. Moreover, RVCZ is highly effective against multi-azole-resistant strains that encode a protein with a G344S substitution in ERG11. Consequently, RVCZ has considerable potential for use as a therapeutic agent for multi-azole resistant cryptococcosis.

引用

页码：11 / 13

页数：3

共 16 条

[1]

[Anonymous], 2008, Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts

[2]

Third Informational Supplement. CLSI document M27-S3, P28

[3] Trends in antifungal susceptibility testing using CLSI reference and commercial methods [J].

Canton, Emilia ;

Espinel-Ingroff, Ana ;

Peman, Javier .

EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (01) :107-119

[4] Increasing trend of fluconazole-non-susceptible Cryptococcus neoformans in patients with invasive cryptococcosis: a 12-year longitudinal study [J].

Chen, Yi-Chun ;

Chang, Tzu-Yao ;

Liu, Jien-Wei ;

Chen, Fang-Ju ;

Chien, Chun-Chih ;

Lee, Chen-Hsiang ;

Lu, Cheng-Hsien .

BMC INFECTIOUS DISEASES, 2015, 15

[5]

Fung-Tomc JC, 1998, ANTIMICROB AGENTS CH, V42, P313

[6] A case of feline cryptococcosis treated with itraconazole [J].

Kano, R ;

Nakamura, Y ;

Watari, T ;

Tsujimoto, H ;

Hasegawa, A .

MYCOSES, 1997, 40 (9-10) :381-383

[7] PCR detection of the Cryptococcus neoformans CAP59 gene from a biopsy specimen from a case of feline cryptococcosis [J].

Kano, R ;

Fujino, Y ;

Takamoto, N ;

Tsujimoto, H ;

Hasegawa, A .

JOURNAL OF VETERINARY DIAGNOSTIC INVESTIGATION, 2001, 13 (05) :439-442

[8] Multi-azole-resistant strains of Cryptococcus neoformans var. grubii isolated from a FLZ-resistant strain by culturing in medium containing voriconazole [J].

Kano, Rui ;

Okubo, Miki ;

Hasegawa, Atsuhiko ;

Kamata, Hiroshi .

MEDICAL MYCOLOGY, 2017, 55 (08) :877-882

[9] First Isolation of Azole-Resistant Cryptococcus neoformans from Feline Cryptococcosis [J].

Kano, Rui ;

Okubo, Miki ;

Yanai, Tokuma ;

Hasegawa, Atsuhiko ;

Kamata, Hiroshi .

MYCOPATHOLOGIA, 2015, 180 (5-6) :427-433

[10] Serotypes and mating types of clinical isolates from feline cryptococcosis in Japan [J].

Okabayashi, K ;

Kano, R ;

Watanabe, T ;

Hasegawa, A .

JOURNAL OF VETERINARY MEDICAL SCIENCE, 2006, 68 (01) :91-94

← 1 2 →